Skip to main content

Advertisement

SpringerLink
Log in

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Oncotype-DX assay has never been validated for BRCA mutation carriers. This study compares the recurrence score (RS) distribution in BRCA-positive breast cancer patients with that of a general population (GP) of patients and reports their outcomes. Eligible patients were BRCA carriers who performed the Oncotype-DX assay. Two sets of databases were cross-linked: BRCA carriers at Rabin Medical Center and Sheba Medical Center with Oncotype-DX tests performed through Clalit Health Services HMO, from 2003 to 2015. Fifty-eight BRCA patients were included (20 BRCA1, 38 BRCA2). The GP included 1020 patients. Compared to the GP, BRCA1 patients were younger, had higher rate of grade three tumors, and higher Ki67. BRCA2 patients had lower PR index, higher rate of grade three tumors, and higher Ki67. Among the GP, 52.9, 37.9, and 9.1 % had low, intermediate, and high risk RS, respectively. Corresponding rates were 15, 35, and 50 % in BRCA1 patients, and 18.4, 52.6, and 29 % in BRCA2 patients. Subgroup analysis revealed a similar RS distribution pattern regardless of the nodal status. Median follow-up was 45 months. Four BRCA patients (7 %) developed disease recurrence. RS of these patients were in the intermediate and low range. All recurrences occurred in chemo-naïve patients who had not undergone bilateral oophorectomy. This study revealed significantly different RS distributions between BRCA patients and the GP. RS values shifted toward high and intermediate risk categories. This pattern held regardless of the nodal status and was more pronounced in the BRCA1 group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343:692–695

    Article  CAS  PubMed  Google Scholar 

  2. Easton D, Thompson D, McGuffog L et al (1999) Cancer risks in BRCA2 mutation carriers. Breast cancer linkage consortium. J Natl Cancer Inst 91:1310–1316

    Article  Google Scholar 

  3. Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365

    Article  CAS  PubMed  Google Scholar 

  4. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Begg CB, Haile RW, Borg A et al (2008) Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299:194–201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Milne RL, Osorio A, Cajal TR et al (2008) The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 14:2861–2869

    Article  CAS  PubMed  Google Scholar 

  7. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408

    Article  CAS  PubMed  Google Scholar 

  8. Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949

    Article  CAS  PubMed  Google Scholar 

  9. Malone KE, Daling JR, Neal C et al (2000) Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88:1393–1402

    Article  CAS  PubMed  Google Scholar 

  10. Lakhani SR, Van De Vijver MJ, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310–2318

    Article  CAS  PubMed  Google Scholar 

  11. Palacios J, Honrado E, Osorio A et al (2003) Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9:3606–3614

    CAS  PubMed  Google Scholar 

  12. Lynch BJ, Holden JA, Buys SS et al (1998) Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 29:1140–1144

    Article  CAS  PubMed  Google Scholar 

  13. Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034

    Article  CAS  PubMed  Google Scholar 

  14. Armes JE, Trute L, White D et al (1999) Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59:2011–2017

    CAS  PubMed  Google Scholar 

  15. Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17

    Article  CAS  PubMed  Google Scholar 

  16. Osin P, Gusterson BA, Philp E et al (1998) Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 34:1683–1686

    Article  CAS  PubMed  Google Scholar 

  17. Osin PP, Lakhani SR (1999) The pathology of familial breast cancer: immunohistochemistry and molecular analysis. Breast Cancer Res 1:36–40

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Eerola H, Heikkila P, Tamminen A et al (2005) Histopathological features of breast tumours in BRCA1, BRCA2, and in mutation negative breast cancer families. Breast Cancer Res 7:R93–R100

    Article  PubMed  Google Scholar 

  19. Lakhani SR, Easton DF, Stratton MR et al (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast cancer linkage consortium. Lancet 349:1505–1510

    Article  Google Scholar 

  20. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated node-negative breast carcinoma. N Engl J Med 351:2817–2826

    Article  CAS  PubMed  Google Scholar 

  21. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor- positive breast cancer. J Clin Oncol 24:3726–3734

    Article  CAS  PubMed  Google Scholar 

  22. Goldstein Lori J, Gray R, Badve S et al (2008) Prognostic utility of the 21-gene assay in hormone receptor–positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063–4071

    Article  PubMed  PubMed Central  Google Scholar 

  23. Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55–65

    Article  CAS  PubMed  Google Scholar 

  24. Weidner N, Cote RJ, Suster S et al (2009) Modern surgical pathology, 2nd edn. Saunders Elsevier, Philadelphia

    Google Scholar 

  25. Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622

    Article  PubMed  Google Scholar 

  26. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–87

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Rebbeck TR, Levin AM, Eisen A et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475–1479

    Article  CAS  PubMed  Google Scholar 

  28. Eisen A, Lubinski J, Klijn J et al (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23:7491–7496

    Article  PubMed  Google Scholar 

  29. Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Huzarski T, Byrski T, Gronwald J et al (2013) Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31:3191–3196

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, 39 Jabotinski St., Petach Tikva, 49100, Israel

    R. Lewin, A. Sulkes, D. Tsoref, S. Rizel, D. Hendler, V. Neiman, I. Ben-Aharon, D. Margel & R. Yerushalmi

  2. Statistical Consulting Unit, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel

    T. Shochat

  3. Clalit Health Services Headquarters, Tel-Aviv, Israel

    N. Liebermann

  4. The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical Center, Tel-Hashomer, Israel

    E. Friedman

  5. Breast Cancer Service for Young Women, Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel

    S. Paluch-Shimon

  6. Raphael Recanati Genetic Institute, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel

    I. Kedar

Authors
  1. R. Lewin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Sulkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Shochat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Tsoref
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Rizel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Liebermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Hendler
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V. Neiman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I. Ben-Aharon
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S. Paluch-Shimon
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D. Margel
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. I. Kedar
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R. Yerushalmi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Lewin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

The experiment complies with the current laws of the country in which it was performed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lewin, R., Sulkes, A., Shochat, T. et al. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations. Breast Cancer Res Treat 157, 511–516 (2016). https://doi.org/10.1007/s10549-016-3836-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-016-3836-6

Keywords

Search

Navigation